Nevro Announces Enrollment of First Patient in PDN Sensory Study

First Randomized Controlled Trial Specifically Powered to Assess Restoration of Neurological Function in Patients with Intractable Painful Diabetic Neuropathy Breakthrough Device Designation Provides Expedited Review for Marketing Application to Expand Nevro's FDA Labeling REDWOOD CITY,...

Click to view original post